NewAmsterdam Pharma Company N.V. (NAMSW) Free cash flow 2021–2025
NewAmsterdam Pharma Company N.V. (NAMSW) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$148.0MFY2025 · since FY2021: -$29.5M → -$148.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$148.0M | +7.0% |
| FY2024 | -$159.2M | -12.7% |
| FY2023 | -$141.2M | -1452.4% |
| FY2022 | $10.4M | +135.4% |
| FY2021 | -$29.5M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More NAMSW financial trends
NAMSW RevenueNAMSW Net incomeNAMSW Net marginNAMSW Gross profitNAMSW Gross marginNAMSW Operating incomeNAMSW Operating marginNAMSW Operating cash flowNAMSW Capital expendituresNAMSW Return on equityNAMSW Stock buybacksNAMSW Dividends paidNAMSW Total assetsNAMSW Total liabilitiesNAMSW Shareholders’ equityNAMSW overview →